CureVac News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

30.03.22	CureVac, GSK Begin Clinical Trial For Second-Generation COVID-19 Vaccine Candidate, CV2CoV (RTTNews)
30.03.22	DGAP-News: CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV (EQS Group)
30.03.22	DGAP-News: CureVac und GSK starten klinische Entwicklung des COVID-19-Impfstoffkandidaten der zweiten Generation, CV2CoV (EQS Group)
30.03.22	Report of foreign issuer [Rules 13a-16 and 15d-16] (RSS)
01.03.22	DGAP-News: CureVac gründet Tochtergesellschaft zur Weiterentwicklung des RNA Printers (EQS Group)
01.03.22	DGAP-News: CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R) (EQS Group)
01.03.22	Form 6-K 1809122 (RSS)
10.02.22	DGAP-News: CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK (EQS Group)
10.02.22	Form 6-K 1809122 (RSS)
18.01.22	Report of foreign issuer [Rules 13a-16 and 15d-16] (RSS)
17.01.22	DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry (EQS Group)
17.01.22	DGAP-News: CureVac Chief Technology Officer verfolgt neue Karriere ausserhalb der Biotech- Branche (EQS Group)
13.01.22	General statement of acquisition of beneficial ownership (RSS)
13.01.22	Form 6-K 1809122 (RSS)
07.01.22	Form 6-K 1809122 (RSS)
03.01.22	Report of foreign issuer [Rules 13a-16 and 15d-16] (RSS)
09.12.21	Direxion Launches mRNA ETF (MSGR) (PR Newswire)
18.11.21	DGAP-News: CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2021 und informiert über das laufende Geschäft (EQS Group)
18.11.21	DGAP-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update (EQS Group)
18.11.21	CureVac: CV2CoV Shows Comparable Antibody Levels To Licensed MRNA Vaccine In Preclinical Study (RTTNews)
18.11.21	DGAP-News: CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine (EQS Group)
10.11.21	DGAP-News: CureVac präsentiert Daten auf SITC Konferenz aus Phase-1-Studie von Onkologie-Kandidat CV8102, die systemische Immunantwort zeigen (EQS Group)
10.11.21	DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response (EQS Group)
12.10.21	CureVac To Withdraw First-generation COVID-19 Vaccine Candidate From EMA Approval Process (RTTNews)
16.08.21	CureVac Posts Wider H1 Operating Loss; CV2CoV Shows Improved Immune Response In Preclinical Study (RTTNews)
30.06.21	CureVac Appoints Malte Greune As COO (RTTNews)
23.06.21	CureVac Says Ingmar Hoerr Withdraws Candidacy For Nomination To Supervisory Board - Quick Facts (RTTNews)
29.05.21	CureVac Says COVID-19 Vaccine Passed First Analysis (RTTNews)
26.05.21	CureVac Posts Sharply Wider Loss In Q1 - Quick Facts (RTTNews)
13.05.21	CureVac Says CV2CoV Showed High Immunogenicity Against Virus Variants In Preclinical Study (RTTNews)
15.04.21	CureVac Posts Wider Loss In Q4 (RTTNews)
23.03.21	CureVac: CVnCoV Vaccine Candidate Protects Against South African Variant In Preclinical Study (RTTNews)
22.03.21	CureVac Expands COVID-19 Vaccine Candidate Analyses To Include Phase 2b/3 Variant Specification (RTTNews)
05.02.21	CureVac, UK To Collaborate On Development Of Vaccines Against SARS-CoV-2 Variants (RTTNews)
03.02.21	GSK, CureVac To Develop MRNA COVID-19 Vaccines (RTTNews)
28.01.21	Stock Alert: CureVac Declines 7%; Prices Public Offering (RTTNews)
11.01.21	Pre-market Movers In Healthcare Sector: TRXC, JAGX, ALRN, BNGO, MBRX, APDN… (RTTNews)
08.01.21	Pre-market Movers In Healthcare Sector: MRUS, OGEN, JAGX, CVAC, SRPT… (RTTNews)
07.01.21	Stock Alert: CureVac Jumps 13% On Partnership With Bayer To Develop Covid Vaccine (RTTNews)
14.12.20	CureVac Begins Phase 2b/3 Study For Development Of COVID-19 Vaccine - Quick Facts (RTTNews)
01.12.20	MRNA Faces AdCom On Dec.17, NVAX To Begin Phase 3 COVID Vaccine Trials In US, Mexico, AMGN On Watch (RTTNews)
23.11.20	Wacker Chemie To Manufacture CureVac COVID-19 Vaccine Candidate At Amsterdam Site (RTTNews)
17.11.20	Pre-market Movers In Healthcare Sector: LXRX, NEPT, VXRT, BNTX, CVAC… (RTTNews)
16.11.20	Pre-market Movers In Healthcare Sector: OBSC, CEMI, ABUS, CVAC, ADMP… (RTTNews)
16.11.20	COVID-19 Vaccines - The Blues And Ease Of Cold Storage (RTTNews)
13.11.20	AZN's Repurposed COVID-19 Drug Fails, NAVB On Watch, CVAC Rallies On Storage Advantage Of CVnCoV (RTTNews)
03.11.20	AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial (RTTNews)
30.09.20	Stock Alert: CureVac Up 6% After Initiating Phase 2 Trial Of COVID-19 Vaccine (RTTNews)
30.09.20	CureVac Initiates Phase 2 Trial Of COVID-19 Vaccine (RTTNews)
29.09.20	After Market Hours: Jiayin Group, Comtech, CureVac Gain; Progress Software, Owens & Minor Slip (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

16:02		Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: Hätte sich ein Johnson Johnson-Investment vor 5 Jahren inzwischen rentiert?
31.12.24		Schwache Performance in New York: S&P 500 letztendlich in der Verlustzone
31.12.24		Angespannte Stimmung in New York: Dow Jones liegt zum Handelsende im Minus
31.12.24		Schwache Performance in New York: S&P 500 nachmittags mit Abgaben
31.12.24		NYSE-Handel Dow Jones zeigt sich am Dienstagnachmittag leichter
31.12.24		Analysten sehen für Roche-Aktie schwarz
31.12.24		Analysten sehen bei Fresenius Medical Care (FMC) St-Aktie Potenzial
31.12.24		Wie Experten die Fresenius SE-Aktie im Dezember einstuften

16:02

Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: Hätte sich ein Johnson Johnson-Investment vor 5 Jahren inzwischen rentiert?

31.12.24

Schwache Performance in New York: S&P 500 letztendlich in der Verlustzone

31.12.24

Angespannte Stimmung in New York: Dow Jones liegt zum Handelsende im Minus

31.12.24

Schwache Performance in New York: S&P 500 nachmittags mit Abgaben

31.12.24

NYSE-Handel Dow Jones zeigt sich am Dienstagnachmittag leichter

31.12.24

Analysten sehen für Roche-Aktie schwarz